Cabaletta Bio to Participate in Upcoming December Investor Conferences

PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in December:

  • Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020: A pre-recorded fireside chat with Dr. Nichtberger is now available on the company’s website.
  • Evercore ISI 3rd Annual Virtual HealthCONx Conference on Thursday, December 3, 2020: Live fireside chat with Dr. Nichtberger at 9:15 a.m. ET.

All webcasts of presentations are available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentations, a replay of the webcasts will be available on the website for 90 days.

About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTesTM phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com


Primary Logo

Source: Cabaletta Bio

The press releases contained in this section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Cabaletta disavows any obligation to update the information contained in such press releases after the date of their issuance.